Officials at the Wisconsin Alumni Research Foundation (WARF) noted that this licensing agreement with BioTime demonstrates that commercial interest in human embryonic stem cells remains strong. With this agreement, WARF now has completed 23 licensing agreements for stem cell technologies with 17 companies.
Michael West, BioTime’s CEO, said: “I am pleased to be able to work with WARF to commercialize our technology in the research market. The license of the WARF patents will allow us to manufacture and commercialize human embryonic stem cell-derived cell types and related products for scientists to use in research and in drug discovery.”